Brickell Biotech, Inc., a Miami, FL-based clinical-stage pharmaceutical company focused on the development of therapeutics for dermatology markets, raised $10m in Series C financing.
Brickell’s Chairman, Charlie Stiefel, former Chairman and CEO of Stiefel Laboratories (acquired by GSK in 2009), led the offering with saw participation from existing investors, management, and others.
The funds will be used to support the growth and continued development of its pipeline.
Led by Reginald Hardy, President, Brickell Biotech focuses on the development and commercialization of innovative pharmaceutical products for the treatment of skin diseases. It is advancing new molecular entities in dermatology for hyperhidrosis, atopic dermatitis, and acne. Following the company’s IND submission to the FDA in December 2014, it has initiated a randomized, double-blind, vehicle-controlled 180-patient Phase 2b clinical trial in patients with primary axillary hyperhidrosis in which it will compare three concentrations of BBI-4000 (a novel topical soft anticholinergic) to vehicle.